Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

Benzinga Newsdesk www.benzinga.com Negative 62.1%

Neg 62.1% Neu 0% Pos 0%

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $3.7 to $3.2.